|Bid||22.79 x 800|
|Ask||57.42 x 1300|
|Day's Range||56.50 - 58.83|
|52 Week Range||50.96 - 117.86|
|Beta (5Y Monthly)||0.95|
|PE Ratio (TTM)||N/A|
|Earnings Date||Apr 27, 2022 - May 02, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||103.71|
Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that, effective on May 1, 2022, the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 40,684 shares of its common stock and an aggregate of 20,335 restricted stock units (RSUs) to twenty-three new employees under Blueprint Medicines' 2020 Inducemen
Blueprint Medicines' (BPMC) earnings meet estimates while revenue beat the same for the first quarter of 2022. Stock up.
Blueprint Medicines (BPMC) delivered earnings and revenue surprises of 0% and 45.15%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?